SPRC (SciSparc) Tariff Resilience Score: 7/10 (As of Aug. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SPRC SciSparc Ltd SPRC
39 GF Score
Price $6.50
GF Value $3.03
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is SciSparc Tariff Resilience Score?

SciSparc SPRC -2.21% 39 Tariff Resilience Score is 7 as of Aug. 28, 2026. GuruFocus rates SPRC with a GF Score™ of 39/100 and a GF Value™ of $3.03 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,361 Biotechnology companies, SciSparc ranks better than 90.3% on this metric.

SciSparc has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

SciSparc has SciSparc operates in the pharmaceutical sector, which is generally less affected by tariffs. The company can mitigate risks through alternative suppliers and has limited direct exposure to manufacturing tariffs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes SciSparc might have Highly Resilient.

SciSparc  (NAS:SPRC) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

SciSparc Tariff Resilience Score Related Terms

SPRC vs ACUT, ONCO, PPCB: Tariff Resilience Score Comparison

For the Biotechnology subindustry, SciSparc's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SciSparc Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SciSparc's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where SciSparc's Tariff Resilience Score falls into.


SPRC
39GF Score
SciSparc Ltd SPRC
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
SciSparc (SPRC) has a Tariff Resilience Score of 7 as of Aug. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, SciSparc ranks #132 out of 1361 companies in the Biotechnology industry, placing it in the top 9.7%.
Is SciSparc's Tariff Resilience Score too high?
SciSparc's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. SciSparc's value of 7 is 75% above this industry median. Based on the distribution chart, SciSparc ranks #132 out of 1361 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SciSparc has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SciSparc's Tariff Resilience Score compare to ACUT and ONCO?
According to the Biotechnology industry distribution chart, SciSparc ranks #132 out of 1361 companies for Tariff Resilience Score. This places SciSparc in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. SciSparc's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,361 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SciSparc's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SciSparc's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SciSparc stock overvalued right now?
Based on GuruFocus' analysis, SciSparc (SPRC) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.03, compared to a current price of $6.50 — trading 114.6% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. SciSparc's overall GF Score™ is 39/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For SciSparc (SPRC), the current Tariff Resilience Score is 7 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SciSparc (SPRC) Overvalued in 2026?

Based on GuruFocus' analysis, SciSparc stock appears to be overvalued. The current stock price of $6.50 is trading 114.6% above its estimated GF Value™ of $3.03. GuruFocus considers SciSparc to be Significantly Overvalued.

Key valuation signals for SPRC:

  • Tariff Resilience Score: 7
  • GF Value™: $3.03 vs. price of $6.50 (114.6% above fair value)
  • GF Score™: 39/100 with 8 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1361)

No single metric tells the full story. See the SPRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SciSparc Business Description

Address 20 Raul Wallenberg Street, Tower A, 2nd Floor, Tel Aviv, ISR, 6971916
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
39GF Score

Get the complete analysis for SPRC

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.50
Price
$3.03
GF Value